NEWS & VIEWS

Global private equity and venture capital news and research

Posts Tagged ‘5AM Ventures’

16 June 2014

Canaan, 5AM Ventures lead $32m Series A for anti-smoking company

cigarette-butt-1021547-m A pair of venture capital firms have led a $32m investment in a company offering behavioural support for smokers looking to break the habit.

14 May 2014

Ceterix Orthopaedics venture backers re-up through $18m financing

Bone Therapeutics A trio of venture capital firms have renewed their commitment to surgical tool maker Ceterix Orthopaedics through an $18m financing round.

17 April 2014

Venture capital-backed Epirus raises $36m, merges with Nasdaq-listed Zalicus

biotech_lrg Boston-based startup Epirus Biopharmaceuticals has secured $36m in a Series B round led by Livzon Mabpharm and agreed to merge with Nasdaq-listed group Zalicus.

28 March 2014

Venture firms renew commitment to RuiYi through $15m Series B round

dna Sino-American medical research business RuiYi has picked up another $15m of financing through a Series B round thanks to renewed commitments from its existing backers.

28 March 2014

Biopharma developer scPharmaceuticals seals $16m Series A VC round

Biopharmaceutical company scPharmaceuticals has closed a $16m Series A venture financing round co-led by life sciences investors 5AM Ventures and Lundbeckfond Ventures.

4 December 2013

5AM Ventures closes biggest-ever fund

life science test tube_sq 5AM Ventures has closed its fourth fund on $250m, making it the largest vehicle ever raised by the biotech-focused firm.

17 October 2013

Biodesy raises $15m Series A from 5AM Ventures, Pfizer, Roche

biotech_lrg Biotech business Biodesy has raised a $15m Series A round from venture capital firms 5AM Ventures, Pfizer Venture Investments and Roche Venture Fund.

17 October 2013

5AM Ventures plots pacey $240m fundraise for fourth vehiclep

biotech_lrg California-based life sciences investor 5AM Ventures is looking to pull in $240m of new capital in what it expects will be a swift fundraise, AltAssets has learned.

19 July 2013

OrbiMed Advisors leads $30m for Audentes Therapeutics

OrbiMed Advisors has led a $30m Series A round for San Francisco-based biotech company Audentes Therapeutics, which develops treatments for rare muscle diseases.

10 June 2013

AstraZeneca acquires VC-backed Pearl Therapeutics for $1.15bn

Venture capital-backed pharmaceutical company Pearl Therapeutics has been acquired by sector major AstraZeneca for $1.15bn.

Page 1 of 212

Legals & Terms of UsePrivacy Policy


AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: Zetland House, 5-25 Scrutton St, London EC2A 4HJ
Content is © AltAssets 2000-2014